378 related articles for article (PubMed ID: 22708926)
1. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
[TBL] [Abstract][Full Text] [Related]
2. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
Ookubo M; Yokoyama H; Kato H; Araki T
Mol Cell Endocrinol; 2009 Nov; 311(1-2):62-8. PubMed ID: 19631714
[TBL] [Abstract][Full Text] [Related]
3. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
4. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
5. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
6. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
9. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Oeckl P; Scheffold A; Lechel A; Rudolph KL; Ferger B
Neuroreport; 2014 Mar; 25(5):335-9. PubMed ID: 24525820
[TBL] [Abstract][Full Text] [Related]
10. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
13. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Gao L; Díaz-Martín J; Dillmann WH; López-Barneo J
Neuroscience; 2011 Oct; 193():323-9. PubMed ID: 21782904
[TBL] [Abstract][Full Text] [Related]
15. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.
Zhang HN; An CN; Zhang HN; Pu XP
Neurosci Lett; 2010 Apr; 474(2):99-103. PubMed ID: 20227465
[TBL] [Abstract][Full Text] [Related]
16. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Muthian G; Mackey V; King J; Charlton CG
Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on retinal dopaminergic system in mice.
Hamilton WR; Trickler WJ; Robinson BL; Paule MG; Ali SF
Neurosci Lett; 2012 May; 515(2):107-10. PubMed ID: 22414866
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
[TBL] [Abstract][Full Text] [Related]
19. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A
Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291
[TBL] [Abstract][Full Text] [Related]
20. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
